U.S. FDA Approves SIMPONI® (golimumab) for Pediatric Ulcerative Colitis
October 7, 2025 — Horsham, Pa. — Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved SIMPONI® (golimumab) for the treatment of children with moderately to severely active ulcerative colitis (UC) who weigh at least 15 kilograms (approximately 33 pounds). This marks an important milestone for pediatric patients who have…